SCN2A Foundation
Clinical Trial Pre-Screener

Could your child be eligible for the EMBRAVE 3 study?

Answer a few brief questions to see if your child may qualify. This takes about two minutes and helps us connect your family with the right next step.

Key Eligibility Criteria
1
Birth through 18 years old.
2
Confirmed SCN2A gene mutation, with seizure onset in the first 3 months of life.
3
At least 4 motor seizures in the past 4 weeks.
Step 1 of 6 17%
Eligibility — Criterion 1

How old is your child?

EMBRAVE 3 enrolls participants from birth through age 18.

Eligibility — Criterion 2

Has your child received a confirmed SCN2A gene mutation diagnosis?

This requires genetic testing showing a pathogenic or likely pathogenic SCN2A variant.

A confirmed diagnosis means a genetic test — such as a gene panel or whole exome sequencing — identified a mutation in the SCN2A gene. If you're unsure, a neurologist or geneticist can review your child's records.
Eligibility — Criterion 2 (continued)

When did your child's seizures first begin?

EMBRAVE 3 specifically targets early-onset SCN2A DEE, where seizures began in the first 3 months of life.

Eligibility — Criterion 3

How many motor seizures has your child had in the past 4 weeks?

Motor seizures involve visible movement — jerking, stiffening, twitching, or falling. The study requires at least 4 in the 4 weeks prior to screening.

If you track seizures in a diary or app, use that number. If not, make your best estimate — the study team will verify this during the formal screening process.
Location

Where is your family located?

EMBRAVE 3 has study sites in the United States, Italy, Germany, and the United Kingdom.

Contact Information

How should the study team reach you?

Your information will only be used to connect you with the EMBRAVE 3 study team. We will never sell or share your data for any other purpose.

Please enter your first name.
Please enter your last name.
Please enter a valid email address.
Please select your relationship to the patient.
Required Consents
I consent to being contacted by the SCN2A Foundation and/or the EMBRAVE 3 study team regarding my child's potential eligibility for this clinical trial. *
I understand and agree that my contact information and pre-qualification responses will be shared with Praxis Precision Medicines and/or a designated EMBRAVE 3 clinical study site for the purpose of follow-up regarding study participation. * *
I have read and agree to the SCN2A Foundation's Privacy Policy & Terms of Use. * *
I understand that this form does not constitute medical advice and does not determine my child's eligibility for the study. Final eligibility decisions are made solely by the study site medical team.

Outside the study age range

EMBRAVE 3 enrolls participants between birth and age 18. Based on your answer, your child may not meet this criterion at this time.

Explore other resources

Confirmed SCN2A diagnosis required

EMBRAVE 3 requires a confirmed SCN2A gene mutation in your child. If genetic testing is in progress or hasn't been done yet, we encourage you to complete that process — then come back and check eligibility again.

Explore other resources

Seizure onset timing

EMBRAVE 3 is specifically designed for early-onset SCN2A DEE, where seizures begin within the first 3 months of life. This study may not be the right fit — but other studies and resources may help.

Seizure frequency

EMBRAVE 3 requires at least 4 motor seizures in the 4 weeks before screening. This criterion is measured at the time of official screening — it's worth speaking with the study team if your child's frequency fluctuates.

Study site availability

Active EMBRAVE 3 sites are currently in the US, Italy, Germany, and the UK. If you're located elsewhere, please leave your contact info — additional sites may open, and we want to stay in touch.

You're on your way.

Based on your responses, your child may meet the key eligibility criteria for EMBRAVE 3. The next step is to schedule a call with a Praxis Nurse Navigator to walk through the formal screening process.

Schedule your call with a Praxis Nurse Navigator →
About this form. This pre-screener is operated by the SCN2A Foundation (scn2afoundation.org), an independent 501(c)(3) nonprofit organization. It is not affiliated with, endorsed by, or operated by Praxis Precision Medicines, Inc. Submitting this form does not guarantee eligibility or enrollment. All eligibility determinations are made solely by qualified medical personnel at an EMBRAVE 3 study site. This form does not constitute medical advice.